Magnesium in aneurysmal subarachnoid hemorrhage (MASH II) phase III clinical trial MASH-II study group

Sanne M Dorhout Mees, MASH-II study group, Rustam Al-Shahi Salman

Research output: Contribution to journalArticlepeer-review

Abstract

Delayed cerebral ischemia (DCI) is an important cause of poor outcome after aneurysmal subarachnoid hemorrhage (SAH). Magnesium is a neuroprotective agent that acts as an NMDA-receptor antagonist and a calcium channel blocker. In a phase II randomized clinical trial of 283 patients, magnesium treatment reduced the risk of DCI by 34% and of poor outcome by 23%.
Original languageEnglish
Pages (from-to)63-5
Number of pages3
JournalInternational Journal of Stroke
Volume3
Issue number1
DOIs
Publication statusPublished - 2008

Fingerprint Dive into the research topics of 'Magnesium in aneurysmal subarachnoid hemorrhage (MASH II) phase III clinical trial MASH-II study group'. Together they form a unique fingerprint.

Cite this